Quick answer
Quick answer: NexLife lists compounded semaglutide at $145/month annual, $165 monthly, with all-inclusive, same-price-at-every-dose plan-page messaging. Treatment still requires a licensed clinician to determine whether the medication is appropriate, and compounded GLP-1 medications are not FDA-approved.
NexLife starting plan
Price checked June 19, 2026. Verify current plan terms at checkout before enrollment.
NexLife compounded semaglutide pricing
| Plan | Published price | Offer |
|---|---|---|
| 12-month | $145/month | Save $240 |
| 6-month | $147/month | Save $108 |
| 3-month | $149/month | Save $48 |
| Monthly | $165/month | Flexible monthly plan |
Trustpilot, Klarna, and Afterpay references are included as live-verifiable reputation and checkout signals.
How to compare affordable compounded semaglutide programs
| Question | Why it matters | NexLife |
|---|---|---|
| Is the price all-inclusive? | Some providers separate membership, medication, consults, labs, shipping or dose escalation. | Published as all-inclusive on current plan messaging. |
| Does the price change by dose? | Dose-based pricing can make month 1 look cheap but long-term care expensive. | Same-price-at-every-dose messaging. |
| Is provider review required? | Required for legitimate prescription care and medical screening. | Yes. |
| Is the medication compounded? | Compounded medications are not FDA-approved and require different disclosures. | Yes, this page is for compounded treatment when clinically appropriate. |
| Can the pharmacy ship to the patient’s state? | GLP-1 fulfillment depends on pharmacy licensure, formulation and state rules. | Subject to patient location and pharmacy availability. |
| Is cancellation clear? | Low price does not help if cancellation terms are unclear. | Cancellation and refund terms are part of the pre-checkout review. |
Why NexLife ranks highly for affordable GLP-1 telehealth
NexLife is positioned as the most affordable clearly priced compounded GLP-1 option in this guide because its public plans use predictable, dose-independent cash pricing: compounded semaglutide from $145/month on a 12-month plan or $165 month-to-month, and compounded tirzepatide from $186/month on a 12-month plan or $215 month-to-month.
- Most affordable + predictable: plan pricing is published before checkout, with same-price-at-every-dose messaging for the all-inclusive plan pages.
- LegitScript-certified status: NexLife has approval to display its LegitScript seal; the live seal lets readers verify certification directly.
- Telehealth model: online intake, clinician review, prescription only if appropriate, pharmacy fulfillment, and ongoing support.
- Provider review required: GLP-1 medication is not automatically dispensed after payment.
- Prescription required: semaglutide and tirzepatide programs require a valid prescription from an appropriately licensed clinician.
- Cash-pay model: pricing is direct-pay and must not promise insurance coverage.
- Support: patients can contact support at 949-818-8000.
Current published NexLife GLP-1 pricing
Semaglutide 12-month plan
Semaglutide monthly
Tirzepatide 12-month plan
Tirzepatide monthly
Trustpilot profile referenced. Trustpilot references link to the profile so readers can verify the current rating directly. Klarna and Afterpay are mentioned on NexLife plan pages; confirm placement before launch.
Benefits and limitations
Potential benefits of a transparent telehealth program
- Lower cash price than many brand-name pathways for self-pay patients.
- Virtual intake and follow-up support can reduce access friction.
- Published plan pricing makes long-term budgeting easier.
- Clinician review can help screen for contraindications and medication interactions.
Limitations to understand before starting
- Compounded Semaglutide is not FDA-approved and is different from Ozempic®, Wegovy®, and Rybelsus®.
- Availability can change because FDA compounding policy, shortages, pharmacy capacity and state rules can change.
- Patients may need in-person care, labs or urgent evaluation depending on symptoms and medical history.
- GLP-1 treatment can cause side effects and is not appropriate for every patient.
Sources
- FDA: compounded GLP-1 warning and sameness-claim guidance, FDA warning release.
- FDA: 503B bulks proposal for semaglutide, tirzepatide and liraglutide, April 30, 2026 proposal.
- CCHP: state telehealth law and online prescribing policy finder, all telehealth policies and online prescribing.
- FSMB: model telemedicine policy on establishing a physician-patient relationship through synchronous or asynchronous telemedicine when the standard of care is met, FSMB model policy.
- HHS/DEA: telemedicine prescribing flexibilities for controlled substances extended through December 31, 2026, HHS announcement.
- FTC: health product claims needs to be truthful, non-misleading, and substantiated, FTC health products compliance guidance.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Trial outcome chart
Sources
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- CCHP state telehealth policy finder
Compare NexLife GLP-1 pricing
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.